dalnacogene ponparvovec
AXP000256.1 · Viral vector gene therapy
- Platform
- AAV vector (capsid not stated in the sources seen)
- Targets
- F9
- Originator
- Belief BioMed
- Sponsor
- Belief BioMed
Names
Virus
- Role
- In vivo gene transfer
- Family
- Parvoviridae
- Virus
- adeno-associated virus
- Replication
- non replicating
- Transgenes
- F9
- Route
- intravenous
- Source
- evidence
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| NMPA | CN | 2025-04 | approved | XinJiuning | Adults with moderate to severe haemophilia B (congenital factor IX deficiency) | source |
| other | MO | 2026-03 | approved | XinJiuning | Adults with moderate to severe haemophilia B, approved by Macao's Pharmaceutical Administration Bureau | source |
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05709288 | Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old | Recruiting | Phase 1 | 2023-03-23 | 2035-06 | 9 | Hemophilia B |
Unconfirmed matches (2)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT05203679 | Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug | Active not recruiting | Phase 2/3 | 2021-12-30 | 2024-04-16 | 32 | Hemophilia B | name in intervention: BBM-H901 |
| NCT04135300 | Gene Therapy for Chinese Hemophilia B | Completed | 2019-10-16 | 2022-01-07 | 10 | Hemophilia B | name in intervention: BBM-H901 |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41266685 | Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials. | Nature medicine | 2026 | name in abstract: BBM-H901 |
| PMID 42749889 | Factor IX Padua AAV gene therapy in adolescents with hemophilia B: a phase 1 trial. | Nature medicine | 2026 | cited by trial NCT05709288 |
| PMID 35598604 | Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial. | The Lancet. Haematology | 2022 | name in abstract: BBM-H901 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41381305 | Liver dysfunction in AAV-mediated Hemophilia B gene therapy: Mechanisms and management strategies. | Blood reviews | 2026 | name in abstract: dalnacogene ponparvovec |
| PMID 42984386 | Adeno-associated virus gene therapy for hemophilia B: a comparative appraisal of the licensed products. | Haematologica | 2026 | name in abstract: dalnacogene ponparvovec |
| PMID 41180128 | Chinese guidance for the clinical application of adeno-associated virus vector-based gene therapy for hemophilia B (2025). | Blood science (Baltimore, Md.) | 2025 | name in abstract: dalnacogene ponparvovec |
Notes
China's first approved rAAV gene therapy and its first for a rare disease: an AAV vector delivering an optimised factor IX gene to hepatocytes, approved by the NMPA in April 2025 for adults with moderate to severe haemophilia B, with Takeda China commercialising it. Approved in Macao in March 2026. Brand name XinJiuning. The capsid serotype is not given in the sources seen, so `strain` is empty.
How to cite
dalnacogene ponparvovec (AXP000256.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000256.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.